Prevalence of calcific aortic valve disease in the elderly and associated risk factors: A population-based study in a Mediterranean area
Por:
Ferreira-González I., Pinar-Sopena J., Ribera A., Marsal J.R., Cascant P., González-Alujas T., Evangelista A., Brotons C., Moral I., Permanyer-Miralda G., García-Dorado D., Tornos P.
Publicada:
1 ene 2013
Resumen:
To determine the prevalence of aortic valve sclerosis (ASC) and stenosis (AS) in the elderly in a Mediterranean area and to identify associated clinical factors. Population cross-sectional study in a random sample of 1068 people =65 years in a Mediterranean area. ASC was categorized as absent, mild-to-moderate, or moderate-to-severe depending on the severity of thickening and calcification. The relation between the severity of ASC and potential risk factors was assessed by multinomial logistic regression analysis. Some degree of thickening and/or calcification was present in 45.4%, of the sample, 73.5% in >85 years. AS prevalence was 3% for the total cohort and 7.4% in >85 years. Adjusting for gender it was found that age, smoking habit, hypertension, waist circumference, and ankle–brachial index <0.9 were associated with degrees of ASC. Except for waist circumference, there was a gradient between the magnitude of association and the severity of ASC. The OR for age was 1.56 (95% CI 1.39–1.76) for mild-to-moderate ASC and 2.03 (95% CI 1.72–2.4) for moderate-to-severe ASC, and for smoking habit 1.59 (95% CI 1.08–2.34) for mild-to-moderate ASC and 2.13 (95% CI 1.19–3.78) for moderate-to-severe ASC. Diabetes and renal impairment were associated with advanced but not with early stages of ASC. The prevalence of ASC and AS in people =65 years is similar to that reported in other regions. The gradient in the association of cardiovascular risk factors with the severity of ASC suggests that they may be causally implied in the pathogenesis of the disease. © 2012, European Society of Cardiology. All rights reserved.
Filiaciones:
Ferreira-González I.:
University Hospital Vall d'Hebron, Barcelona, Spain
CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
Pinar-Sopena J.:
University Hospital Vall d'Hebron, Barcelona, Spain
CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
Ribera A.:
University Hospital Vall d'Hebron, Barcelona, Spain
CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
Marsal J.R.:
University Hospital Vall d'Hebron, Barcelona, Spain
CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
Cascant P.:
University Hospital Vall d'Hebron, Barcelona, Spain
CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
González-Alujas T.:
University Hospital Vall d'Hebron, Barcelona, Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
Evangelista A.:
University Hospital Vall d'Hebron, Barcelona, Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
Brotons C.:
Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain
Moral I.:
Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain
Permanyer-Miralda G.:
University Hospital Vall d'Hebron, Barcelona, Spain
CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
García-Dorado D.:
University Hospital Vall d'Hebron, Barcelona, Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
Tornos P.:
University Hospital Vall d'Hebron, Barcelona, Spain
Red de Enfemedades Cardiovasculares (RECAVA), Spain
|